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Blood glucose levels are tightly controlled by the two pep-
tide hormones glucagon and insulin. At hyperglycaemia,
B-cells in the islets of Langerhans secrete insulin, whereas
islet A-cells release glucagon at hypoglycaemia to stimu-
late e.g. glucose production in the liver. Previously, an
important role for nitric oxide (NO) in the development
of type-1 diabetes mellitus (insulin dependent diabetes
mellitus) was reported [1]. The mechanisms are unknown
whereby NO modulates islet (mal-)function. We hypoth-
esized that NO signals via the cGMP/cGMP kinase I
(cGKI) pathway to modulate the endocrine control of
blood glucose levels. Glucose homeostasis was studied in
the conventional cGKI knockouts (KOs) and in cGKI res-
cue mice (RM) [2] in comparison to age- and littermate
controls. The cGKI mutant mice were significantly hyper-
glycemic at fasting. Further in vivo analysis of RM revealed
no changes of the serum insulin levels, but the serum glu-
cagon was significantly increased in comparison to con-
trols. We anticipated that endogenous cGKI could directly
affect the release of glucagon, because immunofluores-
cence of Langerhans islets demonstrated that the cGKI
protein localized mainly to the glucagon-secreting A-cells
in control mice, but was absent from B-cells and not
detectable in the islets of gene-targeted cGKI mice. The
essential beta subunit of the soluble guanylyl cyclase
(sGCβ1) [3] and the cGMP-degrading phosphodiesterase-
5 (PDE-5), both important cGMP signaling components
in many cells, were also detectable in A-cells of all geno-
types analyzed. To identify a specific function for the path-
way in A-cells, we measured the hormone output of
isolated islets at physiologically low (6 mM) and high (20
mM) concentrations of glucose. Interestingly, the glucose-
induced suppression of glucagon release was abolished in
islets that lacked cGKI, whereas the total glucagon content
of the islets was not changed.
Taken together, our approach identifies a new function of
the cGMP-cGKI signaling pathway in pancreatic A-cells.
The genetic disruption of islet cGKI results in an abnormal
release of glucagon, which leads to a hyperglycaemic fast-
ing phenotype indicative for a pre-diabetic syndrome.
Acknowledgements
We thank Sabine Brummer and Teodora Kennel for their excellent techni-
cal support.
References
1. Burkart V, Kolb H: Nitric oxide in the Immunopathogenesis of
Type 1 Diabetis.  Handb Exp Pharmacol 2000:525-544.
2. Weber S, Bernhard D, Lukowski R, Weinmeister P, Wörner R,
Wegener JW, Valtcheva N, Feil S, Schlossmann J, Hofmann F, Feil R:
Rescue of cGMP Kinase I Knockout Mice by Smooth Muscle-
Specific Expression of Either Isozyme.  Circ Res 2007,
101:1096-1103.
3. Friebe A, Mergia E, Dangel O, Lange A, Koesling D: Fatal gastroin-
testinal obstruction and hypertension in mice lacking nitric
oxide-sensitive guanylyl cyclase.  Proc Natl Acad Sci USA 2007,
104:7699-7704.
from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications
Regensburg, Germany. 19–21 June 2009
Published: 11 August 2009
BMC Pharmacology 2009, 9(Suppl 1):P40 doi:10.1186/1471-2210-9-S1-P40
<supplement> <title> <p>4th International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/P40
© 2009 Leiss et al; licensee BioMed Central Ltd. 
